Academic literature on the topic 'Differentiated thyroid cancers'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Differentiated thyroid cancers.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Differentiated thyroid cancers"
Nix, P., A. Nicolaides, and A. P. Coatesworth. "Thyroid cancer review 2: management of differentiated thyroid cancers." International Journal of Clinical Practice 59, no. 12 (November 18, 2005): 1459–63. http://dx.doi.org/10.1111/j.1368-5031.2005.00672.x.
Full textKrause, Kerstin, Stefan Karger, Oliver Gimm, Sien-Yi Sheu, Henning Dralle, Andrea Tannapfel, Kurt Werner Schmid, Corinne Dupuy, and Dagmar Fuhrer. "Characterisation of DEHAL1 expression in thyroid pathologies." European Journal of Endocrinology 156, no. 3 (March 2007): 295–301. http://dx.doi.org/10.1530/eje-06-0596.
Full textIftikhar, Haissan, Mubasher Ikram, Adnan Muhammad, and Karim Nathani. "Unusual Presentation of Differentiated Thyroid Cancer Metastasis." International Archives of Otorhinolaryngology 22, no. 02 (July 14, 2017): 167–70. http://dx.doi.org/10.1055/s-0037-1604038.
Full textBusaidy, Naifa Lamki, and Maria E. Cabanillas. "Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive Disease." Journal of Thyroid Research 2012 (2012): 1–12. http://dx.doi.org/10.1155/2012/618985.
Full textHartl, Dana M., Joanne Guerlain, Ingrid Breuskin, Julien Hadoux, Eric Baudin, Abir Al Ghuzlan, Marie Terroir-Cassou-Mounat, Livia Lamartina, and Sophie Leboulleux. "Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer." Cancers 12, no. 11 (November 6, 2020): 3282. http://dx.doi.org/10.3390/cancers12113282.
Full textColevas, A. Dimitrios, and Manisha H. Shah. "Evaluation of Patients with Disseminated or Locoregionally Advanced Thyroid Cancer: A Primer for Medical Oncologists." American Society of Clinical Oncology Educational Book, no. 32 (June 2012): 384–88. http://dx.doi.org/10.14694/edbook_am.2012.32.30.
Full textSuteau, Valentine, Mathilde Munier, Claire Briet, and Patrice Rodien. "Sex Bias in Differentiated Thyroid Cancer." International Journal of Molecular Sciences 22, no. 23 (November 30, 2021): 12992. http://dx.doi.org/10.3390/ijms222312992.
Full textMin, Seonyoung, and Hyunseok Kang. "What's New in Molecular Targeted Therapies for Thyroid Cancer?" Korean Society for Head and Neck Oncology 37, no. 2 (November 30, 2021): 1–9. http://dx.doi.org/10.21593/kjhno/2021.37.2.1.
Full textPark, Jong-Lyul, Seon-Kyu Kim, Sora Jeon, Chan-Kwon Jung, and Yong-Sung Kim. "MicroRNA Profile for Diagnostic and Prognostic Biomarkers in Thyroid Cancer." Cancers 13, no. 4 (February 5, 2021): 632. http://dx.doi.org/10.3390/cancers13040632.
Full textRao, Smitha S., and Sabaretnam Mayilvaganan. "Immuno-oncology of differentiated thyroid cancer." International Journal of Molecular & Immuno Oncology 6 (May 29, 2021): 72–75. http://dx.doi.org/10.25259/ijmio_36_2020.
Full textDissertations / Theses on the topic "Differentiated thyroid cancers"
Sheremet, M. I. "Differential diagnosis of nodular goiter on the background autoimmune thyroiditis and differentiated thyroid cancers." Thesis, БДМУ, 2022. http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/19664.
Full textLeboulleux, Sophie. "Place de l'iode 131 et de l'imagerie scintigraphique dans la prise en charge des cancers différenciés de la thyroïde." Thesis, Paris 11, 2013. http://www.theses.fr/2013PA11T062.
Full textInitial treatment of differentiated thyroid cancer is based on a total thyroidectomy and in many cases on the administration of radioactive iodine. Following total thyroidectomy, radioactive iodine is given, based on the primary tumor characteristics. In case of a very low risk of recurrence it is recommended not to give radioactive treatment. In case of high risk patients, a high activity of radioactive iodine is given after TSH stimulation. In case of intermediate risk patients, two randomized prospective studies (ESTIMABL and HILO) have shown that an activity of 1,1 GBq (30 mCi) given after rhTSH (recombinant human Thyroid Stimulating Hormon) was adequate. A further step is taken towards less treatment has now been undertaken with the ESTIMABL2 study, a prospective randomized study comparing a treatment with 1,1 GBq (30 mCi) of radioactive iodine treatment to follow-up without ablation. In patients with persistent disease, positron emission tomography with computed tomography (PET/CT) is a key examination used for its diagnostic and prognostic value. Foci of FDG uptake can localize residual disease, especially when it does not take up radioactive iodine. In patients in whom the site of recurrence remains unknown after a neck ultrasonography PET/CT with FDG is more sensitive than a post-therapeutic whole body scan performed after the administration of a high activity of radioactive iodine (empiric iodine) and should be considered as the first examination to perform. Injections of rhTSH before doing FDG PET/CT allow to increase the number of lesions detected, however the treatment changes linked to this preparation remains minor. The role of FDG PET/CT in the selection of patients to tyrosine kinase inhibitors (TKI) and to assess metabolic tumor response remains to be explored. The use of TKI to reinduce radioactive iodine uptake is a major research subject for patients with radioactive iodine refractory disease
D'Andréa, Grégoire. "Apport de l'intelligence artificielle, de la protéomique et de la métabolomique dans la prise en charge des cancers thyroïdiens différenciés." Electronic Thesis or Diss., Université Côte d'Azur, 2024. http://www.theses.fr/2024COAZ6011.
Full textThyroid nodules (TN) are common, with only 5-10% being cancerous. The diagnostic strategy for TN is well-established, allowing stratification of their malignancy risk; however, it fails to determine the nature of TN in 20-25% of cases, known as indeterminate thyroid nodules (ITN). This often leads to diagnostic surgery, revealing benign nodules in 66% of cases. Improving the diagnosis of these ITN is therefore crucial. Differentiated thyroid cancers (DTC) have a very good prognosis, thanks to treatments involving surgery and radioactive iodine therapy, which cure the majority of patients. Follow-up of DTC relies on the measurement of serum thyroglobulin (Tg), a complex molecule. However, Tg is not specific to thyroid cancer cells, posing interpretation challenges. Discovering a form of Tg more specific to cancer cells could enhance DTC follow-up and serve as a diagnostic tool.In this context, the objectives of my thesis were: i) to improve the prediction of malignancy risk in NTI using artificial intelligence (AI) algorithms and a metabolomic approach, and ii) to better characterize the post-translational modifications (PTMs) of human Tg to serve as a basis for identifying a Tg specific to thyroid cancer cells, facilitating the identification of recurrences in patients treated for DTC. To achieve this, we first compared the efficacy of AI algorithms to predict the malignancy risk of NTI using clinical data collected from a retrospective multicentric cohort of 1290 patients (1337 TN). The use of a supervised autoencoder achieved the best performance scores with an accuracy of 85.19% (±1.5), an AUC of 82.99% (±1.73), and an F1 score of 84.02% (±1.66). In a second study, we identified a metabolomic signature from thyroid fine-needle aspiration (FNA) samples using tandem mass spectrometry coupled with liquid chromatography (LC-MS/MS), enabling the differentiation between benign and malignant nodules among ITN. The use of the supervised autoencoder on this metabolomic signature achieved remarkable diagnostic performance, with an accuracy of 95.7% (0.842-1), an AUC of 94.5% (0.833-1), and an F1 score of 94.7% (0.842-1). Prospectively, the large-scale validation of the obtained results and the adoption of a hybrid approach combining clinical and metabolomic data (especially from less invasive samples than thyroid FNA) are planned. Finally, we conducted an exhaustive mapping of the PTMs of human Tg using a proteomic approach by nano LC-MS/MS to better understand its complexity. This study revealed a broader spectrum of N-glycosylation, oxidation, and iodination sites than previously reported, providing a valuable resource for future research aimed at understanding the modulation and roles of Tg PTMs. Looking ahead, identifying observable differences in Tg PTMs between healthy and cancerous thyroid cells could lead to the identification of a Tg specific to the latter, facilitating the identification of recurrences in patients treated for DTC and offering diagnostic and therapeutic innovations in thyroid oncology. This thesis thus paves the way for new diagnostic and follow-up strategies based on metabolomics, proteomics, and artificial intelligence in the context of NT and DTC
Lang, Brian. "Cancer staging for differentiated thyroid carcinoma." Click to view the E-thesis via HKUTO, 2006. http://sunzi.lib.hku.hk/hkuto/record/B36916134.
Full textMehrotra, Pallavi. "Molecular characteristics of differentiated thyroid cancer." Thesis, University of Newcastle upon Tyne, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.405074.
Full textChow, Sin-ming, and 周倩明. "Differentiated thyroid cancer in Hong Kong." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2007. http://hub.hku.hk/bib/B41290847.
Full textLang, Brian, and 梁熊顯. "Cancer staging for differentiated thyroid carcinoma." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2006. http://hub.hku.hk/bib/B36916134.
Full textChow, Sin-ming. "Differentiated thyroid cancer in Hong Kong." Click to view the E-thesis via HKUTO, 2007. http://sunzi.lib.hku.hk/hkuto/record/B41290847.
Full textCiappuccini, Renaud. "Apport de l'imagerie fonctionnelle par TEMP/TDM et TEP/TDM dans la prise en charge des cancers différenciés de la thyroïde Incremental Value of a Dedicated Head and Neck Acquisition during 18F-FDG PET/CT in Patients with Differentiated Thyroid Cancer Full text links full-text provider logo Actions Favorites Share Page navigation Title & authors Abstract Conflict of interest statement Figures Similar articles Cited by References Related information LinkOut - more resources EJNMMI Res . 2018 Dec 3;8(1):104. doi: 10.1186/s13550-018-0461-x. Optimization of a dedicated protocol using a small-voxel PSF reconstruction for head-and-neck 18 FDG PET/CT imaging in differentiated thyroid cancer 78 Lymph node involvement in head-and-neck and thyroid cancers with digital PET/CT: the impact of ultra-high definition voxels and point-spread function Tumor burden of persistent disease in patients with differentiated thyroid cancer: correlation with postoperative risk-stratification and impact on outcome 133 18F-Fluorocholine PET/CT is a highly sensitive but poorly specific tool for identifying malignancy in thyroid nodules with indeterminate cytology: The Chocolate study PSMA expression in neovasculature of persistent/recurrent differentiated thyroid cancerin the neck: relationship with radioiodine uptake, 18Fluorodeoxyglucose avidity and outcome." Thesis, Normandie, 2020. http://www.theses.fr/2020NORMC424.
Full textRadioiodine (131I) and 18-Fluorodeoxyglucose (18FDG) are two radiopharmaceuticals used for scintigraphic imaging in differentiated thyroid cancers (DTC). Tumour uptake of each tracer depends on tumour differentiation and aggressiveness. Our goal was to further assess various technical aspects in DTC imaging workup, such as SPECT/CT and PET/CT, point-spread function (PSF), voxel size, digital PET, and to explore further other PET tracers. The aim of the first part was to assess the performance of 18FDG PET/CT for the detection of neck lymph node involvement. A dedicated PET/CT acquisition improved tumour detection compared to the whole-body acquisition. PSF reconstruction allowed detection of smaller cancer deposits and the optimal acquisition duration time was assessed. Using digital PET acquisitions, ultra-thin voxels reconstructions were performed. The impact of ultra-thin voxels and PSF on quantitative values was evaluated. The second part focused on 131I-SPECT/CT and 18FDG-PET/CT imaging, in an attempt to assess tumour burden of persistent disease. Tumor burden was correlated with the postoperative risk and affected the response to therapy. In the third part, another PET tracer, i.e. 18-Fluorocholine (FCH), and a marker of neovasculature, i.e. prostate-specific membrane antigen (PSMA), were studied. FCH PET/CT offered high negative predictive value to reliably exclude cancer in PET-negative nodules with indeterminate cytology and might prevent unnecessary surgeries. Also, PSMA expression assessed with immunohistochemistry was associated with poor prognosis factors. Further studies are needed to confirm new insights of FCH PET and 68Ga-PSMA PET in DTC
Marcelino, Ana Sousa. "Targeting thyroid stimulating hormone receptors in radioiodine resistent de-differentiated thyroid cancer." Thesis, Queen Mary, University of London, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.576914.
Full textBooks on the topic "Differentiated thyroid cancers"
Greene, Frederick L., and Andrzej L. Komorowski, eds. Clinical Approach to Well-differentiated Thyroid Cancers. New Delhi: Springer India, 2012. http://dx.doi.org/10.1007/978-81-322-2568-3.
Full textMancino, Anne T., and Lawrence T. Kim, eds. Management of Differentiated Thyroid Cancer. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-54493-9.
Full textRoman, Sanziana A., Julie Ann Sosa, and Carmen C. Solórzano, eds. Management of Thyroid Nodules and Differentiated Thyroid Cancer. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-43618-0.
Full textRoman, Sanziana A., Wen T. Shen, and Julie Ann Sosa, eds. Controversies in Thyroid Nodules and Differentiated Thyroid Cancer. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-37135-6.
Full textGreene, Frederick L., and Andrzej L. Komorowski. Clinical Approach to Well-differentiated Thyroid Cancers. Springer, 2016.
Find full textGreene, Frederick L., and Andrzej L. Komorowski. Clinical Approach to Well-Differentiated Thyroid Cancers. Springer, 2015.
Find full textGreene, Frederick L., and Andrzej L. Komorowski. Clinical Approach to Well-differentiated Thyroid Cancers. Springer, 2015.
Find full textMancino, Anne T., and Lawrence T. Kim. Management of Differentiated Thyroid Cancer. Springer International Publishing AG, 2017.
Find full textMancino, Anne T., and Lawrence T. Kim. Management of Differentiated Thyroid Cancer. Springer International Publishing AG, 2018.
Find full textRoman, Sanziana A., Julie Ann Sosa, and Carmen C. Solórzano. Management of Thyroid Nodules and Differentiated Thyroid Cancer: A Practical Guide. Springer, 2018.
Find full textBook chapters on the topic "Differentiated thyroid cancers"
D'cruz, Anil, and Richa Vaish. "Surgical Management of Differentiated Thyroid Cancers." In Thyroid Surgery, 105–11. First edition. | Boca Raton : CRC Press, 2020.: CRC Press, 2020. http://dx.doi.org/10.1201/9780429086076-14.
Full textRyś, Janusz, and Joanna Wysocka. "Pathology of Differentiated Thyroid Cancers." In Clinical Approach to Well-differentiated Thyroid Cancers, 5–22. New Delhi: Springer India, 2012. http://dx.doi.org/10.1007/978-81-322-2568-3_2.
Full textWysocki, Wojciech M., Andrzej L. Komorowski, and Frederick L. Greene. "Staging of Differentiated Thyroid Cancer." In Clinical Approach to Well-differentiated Thyroid Cancers, 41–44. New Delhi: Springer India, 2012. http://dx.doi.org/10.1007/978-81-322-2568-3_5.
Full textGwyther, Stephen J. "Imaging in Thyroid Cancer." In Clinical Approach to Well-differentiated Thyroid Cancers, 27–39. New Delhi: Springer India, 2012. http://dx.doi.org/10.1007/978-81-322-2568-3_4.
Full textBurnison, C. Michele. "External Beam Radiation Therapy in the Treatment of Differentiated Thyroid Cancers." In Thyroid Cancer, 271–99. Boston, MA: Springer US, 2011. http://dx.doi.org/10.1007/978-1-4614-0875-8_14.
Full textBarczyński, Marcin. "Surgical Treatment of Thyroid Cancer." In Clinical Approach to Well-differentiated Thyroid Cancers, 55–77. New Delhi: Springer India, 2012. http://dx.doi.org/10.1007/978-81-322-2568-3_7.
Full textIacconi, Pietro, and Carmine De Bartolomeis. "Postoperative Complications in Thyroid Surgery." In Clinical Approach to Well-differentiated Thyroid Cancers, 115–24. New Delhi: Springer India, 2012. http://dx.doi.org/10.1007/978-81-322-2568-3_12.
Full textYip, Linwah, and Sally E. Carty. "Differentiated Thyroid Cancers of Follicular Cell Origin." In Endocrine Neoplasia, 35–56. Boston, MA: Springer US, 2009. http://dx.doi.org/10.1007/978-1-4419-0857-5_3.
Full textKomorowski, Artur, and Andrzej L. Komorowski. "Clinical Evaluation of the Thyroid Gland." In Clinical Approach to Well-differentiated Thyroid Cancers, 23–26. New Delhi: Springer India, 2012. http://dx.doi.org/10.1007/978-81-322-2568-3_3.
Full textGal, Istvan. "Minimally Invasive Approach to the Thyroid." In Clinical Approach to Well-differentiated Thyroid Cancers, 79–91. New Delhi: Springer India, 2012. http://dx.doi.org/10.1007/978-81-322-2568-3_8.
Full textConference papers on the topic "Differentiated thyroid cancers"
Dogra, Akash, Srishti Sharma, Daksh Rawat, Harshit Narang, Satvik Vats, and Vikrant Sharma. "Using XGBoost for Risk Stratification in Differentiated Thyroid Cancer Recurrence Prediction." In 2024 IEEE 3rd World Conference on Applied Intelligence and Computing (AIC), 472–77. IEEE, 2024. http://dx.doi.org/10.1109/aic61668.2024.10731128.
Full textAMIT, MORAN, shorook Na’ara, Tomer Charas, and Ziv gil. "Abstract 2879: PIGU modulates radioactive iodine uptake in differentiated thyroid cancers." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-2879.
Full textStephen, Josena K., Kang Mei Chen, Jason Merritt, Indrani Datta, Dhananjay Chitale, George Divine, and Maria J. Worsham. "Abstract 3361: Methylome differences in differentiated thyroid cancers and benign adenomas." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-3361.
Full textCopland, John, Kendall Schick, Justyna Gleba, Truc Huynh, James Miller, Erin MIller, Aylin Alasonyalilar Demirer, et al. "324 Sensitizing poorly differentiated thyroid cancers to TSHR-CART cell therapy with MEK inhibitors." In SITC 37th Annual Meeting (SITC 2022) Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jitc-2022-sitc2022.0324.
Full textBegić, Amela, and Elma Kučukalić-Selimović. "RADIOIODINE THERAPY OF DIFFERENTIATED THYROID CANCER – PRINCIPLES AND PRACTICE." In Tumori štitnjače u kliničkoj praksi. Akademija nauka i umjetnosti Bosne i Hercegovine, 2016. http://dx.doi.org/10.5644/pi2016.167.04.
Full textK, Bharath, and A. Sai Sabitha. "Predicting Recurrence in Differentiated Thyroid Cancer: A Machine Learning Approach." In 2024 International Conference on Advances in Data Engineering and Intelligent Computing Systems (ADICS). IEEE, 2024. http://dx.doi.org/10.1109/adics58448.2024.10533649.
Full textAllauca, Erika, Vilma Yanchapanta, and Javier Toasa Tapia. "Calculation of accumulated absorbed radiation dose in patients with differentiated thyroid cancer." In PROCEEDINGS OF THE 2ND INTERNATIONAL CONGRESS ON PHYSICS ESPOCH (ICPE-2017). Author(s), 2018. http://dx.doi.org/10.1063/1.5050353.
Full textPark, Gahee, Tae Hyuk Kim, Hae-Ock Lee, Jung Ah Lim, Jae-Kyung Won, Hye Sook Min, Kyu Eun Lee, Do Joon Park, Young Joo Park, and Woong-Yang Park. "Abstract 2134: Standard immunohistochemistry efficiently screens for ALK rearrangements in differentiated thyroid cancer." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-2134.
Full textBouyoucef, Salah, Abdelkrim Talbi, Dalila Mouas, Assia Amimour, Skander Rahabi, and Amel Khelifa. "Crucial Role of Iodine 131 in the Management of Bone Metastasis of Differentiated Thyroid Cancer." In Abstracts for the 18th International Conference on Radiopharmaceutical Therapy (ICRT). Thieme Medical and Scientific Publishers Pvt. Ltd., 2023. http://dx.doi.org/10.1055/s-0043-1769958.
Full textYartey, Miriam N. Y., Clement Korsah, and Alfred O. Ankrah. "A Clinical and Ethical Dilemma during Radioiodine Therapy for Well-Differentiated Thyroid Cancer—A Case Report." In Abstracts for the 18th International Conference on Radiopharmaceutical Therapy (ICRT). Thieme Medical and Scientific Publishers Pvt. Ltd., 2023. http://dx.doi.org/10.1055/s-0043-1769988.
Full textReports on the topic "Differentiated thyroid cancers"
Alessa, Mohammed, Tayba Wahedi, Jumanah Alsairafi, Nouf Almatrafi, Wisal Shuaib, Johara Alnafie, Fatimah Alzubaidi, and Soha Elmorsy. Prevalence of Thyroid cancer in Saudi Arabis: Systematic review and Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0088.
Full textZhao, Hao, Chunhao Liu, Yanlong Li, and Xiaoyi Li. Prognostic factors for survival in differentiated thyroid cancer with pulmonary metastases: a protocol of systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, February 2022. http://dx.doi.org/10.37766/inplasy2022.2.0026.
Full textWang, Yizhen, Zhicheng Jin, Fang Zhang, and Yangting Mao. The efficacy and influencing factors of radioactive iodine in the treatment of patients with lung metastasis of differentiated thyroid cancer: a meta analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2021. http://dx.doi.org/10.37766/inplasy2021.11.0093.
Full text